Chairs: Prof. Christopher E. Brightling (Leicester (Leicestershire), United Kingdom), Dr Apostolos Bossios (Stockholm, Sweden)

Speakers: Prof. Alvar Agusti Garcia-Navarro (Barcelona, Spain), Dr Rosa Faner (Barcelona, Spain), Prof. Dr Mona Bafadhel (London, United Kingdom)

Fees: Free for ERS members and non-members
Find out more about becoming a member

Overview

Recent breakthroughs in biologic therapies for Chronic Obstructive Pulmonary Disease (COPD) are set to revolutionise treatment approaches. With groundbreaking studies slated for publication in Q3 2025, including findings from the 3TR project (Taxonomy, Treatment, Targets, and Remission - a large-scale public-private partnership aimed at revolutionising treatment for multiple immune-mediated diseases), it's crucial for healthcare professionals to stay ahead of the curve and understand the potential impact on patient care.

Topics

• Cutting-edge research in COPD biologics including 3TR ambitions in the field of COPD
• Precision medicine and treatable traits in COPD
• Innovative approaches to early COPD diagnosis and phenotyping
• Future directions in COPD management

Format

One-hour webinar structured as follows:

1. Welcome and introduction by chairs

2. Early COPD diagnosis, underdiagnosis, misdiagnosis and phenotyping (10 min + 5 min Q&A)

• Speaker: Alvar Agusti
• Discover how precision medicine approaches can advance COPD diagnosis and treatment

3. The Future of COPD Treatment (10 min + 5 min Q&A)

• Speaker: Rosa Faner
• Learn about groundbreaking research initiatives, including 3TR, and their expected outcomes for COPD management

4. Biologics: A Game-Changer for COPD? (10 min + 5 min Q&A)

• Speaker: Mona Bafadel
• Explore the latest studies on biologics and their potential to transform COPD treatment

5. Open Discussion: Shaping the Future of COPD Care (15 min)

• Moderated by Chairs: C. Brightling and A. Bossios
• Engage in a dynamic discussion about the future of COPD management and patient care

Learning outcomes

Following this webinar, participants will be able to:

• Identify emerging biologic therapies for COPD and their potential applications
• Apply principles of precision medicine to COPD management
• Recognise the importance of early diagnosis and accurate phenotyping in COPD
• Evaluate current research gaps and anticipate future developments in COPD treatment

CME credit

An application for accreditation of this webinar has been made to the European Board for Accreditation in Pneumology (EBAP) for 1 CME credit per 1-hour attendance. If accredited, the CME credit will be granted upon attendance of at least 60 minutes during the live webinar only.

What is a webinar?

A webinar closely simulates a lecture-based teaching experience. The speaker can interact with the audience, just as in a classroom setting. During the webinar, you will be asked to share your opinion on issues related to the topic using interactive polls.

All participants will be able to hear the lecturer and see the slides throughout the presentation. As a participant you will be able to pose questions or discuss ideas with the other participants via the text chat facility and the speaker will respond to the questions via the microphone.

Login guidelines

More information will be communicated in due course.

• Please log in to the webinar 20 minutes before it is scheduled to commence. If you have any technical difficulties whilst trying to log in or during the session please contact e-learning@ersnet.org.
• Check Central European Summer Time.
• To achieve the best quality, we recommend to avoid downloading anything from the internet during your connection to the lecture and stopping all other programmes.
• Please also ensure that your audio settings are not set to mute and adjust the volume to a comfortable level.

Disclaimer

The 3TR project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 831434 (3TR). The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

Neither IMI nor the EU, EFPIA or any associated partners are responsibly for any use made of the information presented.